Demis Hassabis's Isomorphic Labs Raises $5 Billion to Build AI-Designed Drugs
Isomorphic Labs, the Alphabet subsidiary led by Demis Hassabis, raised $5 billion in a Series C round, six months after its $2.1 billion raise. The money will go toward clinical trials: the company has more than 20 programs underway, with partners Eli Lilly, Novartis, and Johnson & Johnson. No regulator has yet approved a drug created by AI, so the real test still lies ahead.
AI-processed from TNW; edited by Hamidun News
Isomorphic Labs, an Alphabet company that builds AI for drug discovery, raised $5 billion in a Series C round. This is the second massive check in six months: in May, it raised $2.1 billion. For the industry, this signals that investors are willing to pay upfront for AI biotech, even before the first AI-created drug reaches patients.
Who Invested and What It Means
Greenoaks and Sequoia Capital jointly led the round. Andreessen Horowitz and several new investors joined them, and Alphabet, according to the company, continued to invest significantly. All previous investors took part in the round: Thrive Capital, MGX, GV, CapitalG, Temasek, and the British UK Sovereign AI Fund. Isomorphic said demand exceeded the number of places available in the round.
The company did not disclose its valuation. Bloomberg reported on it earlier this month, but the text available to us does not include a figure, so we won't speculate. Doubling the capital raised in six months suggests investors see the company as an infrastructure bet, not an ordinary startup with a single drug.
What the Company Plans to Do With the Money
Isomorphic grew out of the AlphaFold era. It was founded in 2021 to develop the ideas behind AlphaFold, the Google DeepMind model that predicts the three-dimensional structure of proteins. It now has its own drug design engine, IsoDDE. According to the company, the engine has produced positive preclinical results in its own oncology and immunology programs and with partners. Preclinical means work in cells and animals, not in humans. In total, more than 20 programs are underway. Its pharma partners include Eli Lilly, Novartis, and Johnson & Johnson.
Hassabis told Bloomberg that the goal is a platform that produces "hundreds of drugs a year." For comparison, developing a single conventional drug takes years and costs hundreds of millions of dollars. The idea is for a model to handle the molecule selection that used to rely on trial and error in the lab, with the lab only testing the best candidates.
The second part of the plan is expanding the range of "modalities." So far, the company works mainly with small molecules, meaning conventional pills. Hassabis wants to go further and cover "virtually all modalities," including large biologic molecules such as antibodies.
What Remains Uncertain
In January, Hassabis said the first clinical trials were expected by the end of 2026. He did not give Bloomberg an updated timeline. He only said that regulatory filings are on track and that more news will come in 2027. At the same time, as Bloomberg noted, no regulator anywhere in the world has yet approved a drug designed by AI. Impressive preclinical results guarantee nothing: many drugs fail precisely in human trials.
Sequoia partner Konstantin Buhler explained the bet by saying Isomorphic's models show scaling laws: quality keeps improving as computing power and data are added. This is the same argument on which the large language model market is built, now applied to chemistry and biology. If it holds, compute spending becomes a clear lever, but for now it is an investor's claim, not a public test.
Chips are a separate issue. Bloomberg reports that Jensen Huang's departure from Nvidia last week alarmed some AI companies, which fear for their access to accelerators. Hassabis responded that Isomorphic has "very reliable computing channels." Google designs its own AI chips, which gives its subsidiary a clear advantage.
This round is Isomorphic's first since Hassabis stepped down as CEO of Google DeepMind in August. He is now chair of DeepMind and Alphabet's chief scientist, but he continues to lead Isomorphic.
What This Means for Practitioners
For founders in AI biotech: capital is flowing to platforms with proven scaling and strong pharma partners, not to individual molecules. For developers: AI for science is becoming a distinct field with enormous compute budgets. The main test will come in 2027, when it becomes clear whether the first candidates reach humans and how they perform there.
- Nov 21, 2026Apple Is Building an AI Agent and Making It Harder for Outsiders to Get Access: Permission Now Takes 14 Steps, Not 4
- Nov 21, 2026Gemini 4 Neon shrank the TS Rust binary from 47.44 to 7.97 MB in under 10 hours
- Nov 21, 2026A swimming team captain handed ChatGPT three scheduled tasks and cut her routine work by a multiple
- Nov 21, 2026MIRA Neural Network Renders Rocket League at 20 FPS, but Ping Hits 460 ms
Key Questions Answered
Who Invested and What It Means?
Greenoaks and Sequoia Capital jointly led the round. Andreessen Horowitz and several new investors joined them, and Alphabet, according to the company, continued to invest significantly. All previous investors took part in the round: Thrive Capital, MGX, GV, CapitalG, Temasek, and the British UK Sovereign AI Fund. Isomorphic said demand exceeded the number of places available in the round. The company did not disclose its valuation.
What the Company Plans to Do With the Money?
Isomorphic grew out of the AlphaFold era. It was founded in 2021 to develop the ideas behind AlphaFold, the Google DeepMind model that predicts the three-dimensional structure of proteins. It now has its own drug design engine, IsoDDE. According to the company, the engine has produced positive preclinical results in its own oncology and immunology programs and with partners. Preclinical means work in cells and animals, not in humans. In total, more than 20 programs are underway.
What Remains Uncertain?
In January, Hassabis said the first clinical trials were expected by the end of 2026. He did not give Bloomberg an updated timeline. He only said that regulatory filings are on track and that more news will come in 2027. At the same time, as Bloomberg noted, no regulator anywhere in the world has yet approved a drug designed by AI. Impressive preclinical results guarantee nothing: many drugs fail precisely in human trials.
Test Frontier LLMs & Autonomous Agents in One Workspace
Run Claude Opus 5.5, GPT-6, Gemini 3.1, and DeepSeek side-by-side in Nomad AI (nomadnet.ai) — unified model routing, deep research, and multimodal workflows under one subscription.
The AI world, distilled — once a week
Seven stories that actually mattered, hand-picked. No noise, no reposts, no press releases.
Done! Check your inbox for a confirmation.